1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 1: Outcomes with tirofiban versus DAPT
Outcome Tirofiban % (95% CI) I² DAPT % (95% CI) I² P Value
Thromboembolic complications 3.6 (1.9–5.8) 33 8.5 (4.5–13.0) 88 .04
Hemorrhagic complications 3.5 (1.8–5.6) 28 5.1 (2.6–8.5) 80 .371
Perioperative mortality related to antiplatelet medication 0.8 (0.2–1.6) 15 1.2 (0.7–2.0) 0 .412
Good clinical outcomes 89.0 (74.0–99.0) 91 92.7 (87.1–96.8) 87 .589

Outcome	Tirofiban % (95% CI)	I²	DAPT % (95% CI)	I²	P Value
Thromboembolic complications	3.6 (1.9–5.8)	33	8.5 (4.5–13.0)	88	.04
Hemorrhagic complications	3.5 (1.8–5.6)	28	5.1 (2.6–8.5)	80	.371
Perioperative mortality related to antiplatelet medication	0.8 (0.2–1.6)	15	1.2 (0.7–2.0)	0	.412
Good clinical outcomes	89.0 (74.0–99.0)	91	92.7 (87.1–96.8)	87	.589